trending Market Intelligence /marketintelligence/en/news-insights/trending/CMbVga7k74MzHOxc18W2PA2 content esgSubNav
In This List

TrovaGene director to resign

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


TrovaGene director to resign

TrovaGene Inc. said that Stanley Tennant will resign as a director, effective Dec. 31.

Tennant's resignation is due to personal reasons and not a result of any disagreement with the company, its management or board, TrovaGene said in a Dec. 10 regulatory document.

San Diego-based Trovagene is a clinical-stage biopharmaceutical company focused on developing oncology therapeutics.